Six-year outcomes from EURACAN – ESMO

European Society for Medical Oncology shared a post on LinkedIn:

“ESMOGynae24: Six-year outcomes from EURACAN activity show that implementing MDTs provides opportunities for clinical support and access to treatment alternatives for patients with complex Rare Gynecological Cancers.

The European Reference Network for Rare Adult Cancers (EURACAN) G2 domain is committed to advancing the understanding and treatment of Rare Cancers.

ESMO’s Rare Cancers Working Group partners with EURACAN and other associations to establish rare diseases firmly on the European policy agenda.”

Source: ESMO/LinkedIn

The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information.

ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up.

It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.